Orchestra BioMed Holdings, Inc.
NasdaqGM OBIO
Orchestra BioMed Holdings, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -3.47
-
Orchestra BioMed Holdings, Inc. 52-week high Price to Earnings Ratio (P/E) is -2.70 on December 31, 2024, which is 22.36% above the current Price to Earnings Ratio (P/E).
-
Orchestra BioMed Holdings, Inc. 52-week low Price to Earnings Ratio (P/E) is -6.93 on January 23, 2024, which is -99.42% below the current Price to Earnings Ratio (P/E).
-
Orchestra BioMed Holdings, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -4.11.
| Date | Price to Earnings Ratio (P/E) | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield |
|---|
| CEO | Mr. David P. Hochman |
| IPO Date | Aug. 4, 2020 |
| Location | United States |
| Headquarters | 150 Union Square Drive |
| Employees | 56 |
| Sector | Health Care |
| Industries | |
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email